Edgewise Therapeutics (EWTX) Stock Forecast & Price Target

Edgewise Therapeutics is viewed positively because the June Phase 2 CIRRUS-HCM Part D readout for EDG-7500 showed broad, clinically meaningful gains in oHCM and nHCM across hemodynamics, biomarkers, symptoms, and function, while preserving LVEF and showing no heart-failure events or LVEF below 50% in the reported cohort. The company’s differentiation is strengthened by the possibility of a simpler, potentially echo-light treatment paradigm versus current cardiac myosin inhibitors, which could improve adoption in a large HCM market with roughly 240,000 US patients and an estimated $8 to $10 billion net opportunity at full penetration. Sentiment is further supported by the June sale of sevasemten and the muscular dystrophy portfolio for $1.55 billion upfront and up to $1.1 billion in milestones, which materially strengthens liquidity, fully funds EDG-7500 development through potential approval, and allows Edgewise to focus on a cardiovascular pipeline that now includes EDG-15400 and EDG-003.

Edgewise Therapeutics is a clinical-stage company with no commercial products, so its valuation depends heavily on a single lead program while the pipeline remains early and unproven. The thesis is vulnerable because EDG-7500’s differentiation still rests on a small safety and efficacy dataset, and any failure to replicate Part D results in larger Phase 3 cohorts could erase the case for better regulatory treatment or market penetration. Financial risk is also meaningful: the company may need additional funding, and downside scenarios explicitly suggest the stock could trade near cash if clinical, manufacturing, reimbursement, or competitive pressures undermine the program.